drugset / Trial / NCT01496131
Tecemotide (L-BLP25) in Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
Timeline
- Start
- 2011-10-24
- Primary completion
- 2016-11-25
- Completion
- 2016-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tecemotide | Vaccine | 918 ug | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Goserelin | Other / unclassified | 10.8 mg | Subcutaneous |